CalciMedica and Telperian collaborate to integrate AI to Auxora clinical trials

CalciMedica (CALC) and Telperian, a clinical trial intelligence company, announced a collaboration on the integration of Telperian’s AI engine into the analysis of clinical trial datasets from completed clinical trials of Auxora as well as data set simulations from publications of third-party trials. Auxora, CalciMedica’s lead clinical compound, is a selective small molecule CRAC channel inhibitor being developed for use in patients with acute inflammatory and immunologic illnesses. Auxora has been evaluated in multiple efficacy clinical trials. CalciMedica is currently in discussions with the FDA on a final pivotal trial design for Auxora in AP. Auxora is also currently being evaluated in the Phase 2 KOURAGE trial in patients with acute kidney injury with respiratory failure, with data expected in early 2026. By applying these tools to analyze clinical trial data of Auxora, Telperian will provide deep, data-supported insights into the benefits of treatment with Auxora to different patient subtypes, as well as other discernible patterns and benefits of treatment. These findings will be used to support CalciMedica in the company’s regulatory discussions.